Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAXOMET: Metformin + Docetaxel in Metastatic Castration-Resistant Prostate Cancer
NCT01796028Phase 2Completed
- Sponsor
- Centre Antoine Lacassagne
- Start
- Jan 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metformin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Centre Antoine Lacassagne. Started Jan 2013; status: completed.
02
Drugs
metformin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01796028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796028.